First slide

In order to enhance lab operations, Boehringer Ingelheim announce partnership with Xybion Corporation. The cooperation will enhance process efficiency and data integrity in the Preclinical lab.

  • This partnership will help study planning, protocol, study execution, animal management, data management and regulatory submissions globally.
  • Xybion is a leading software solutions and consulting company dedicated to helping corporations solve business problems and create new capabilities.

The prominent deals and collaborations by Boehringer Ingelheim are mentioned below:

Dec 2020: Boehringer Ingelheim announced the acquisition of Germany based biotech company Labor Dr. Merk & Kollegen. The deal expands Boehringer Ingelheim’s R&D and clinical manufacturing capabilities with a site focused predominantly on ATMP (Advanced Therapy Medicinal Products)-based cancer immunology treatments.

May 2020: Boehringer Ingelheim had announced the acquisition of Northern Biologics Inc., a wholly owned subsidiary of Northern LP. Boehringer Ingelheim with this acquisition will focuse on therapeutic antibodies targeting the tumor microenvironment.

May 2020: Boehringer Ingelheim entered into a collaboration and licensing agreement with CDR-Life to research and develop antibody fragment-based therapeutics for geographic atrophy (GA). GA is a progressive, irreversible retinal disease that occurs in patients with age-related macular degeneration (AMD) for which there is no current treatment. Together, with Boehringer Ingelheim’s expertise in the therapeutic development of biologics and CDR-Life’s strong know-how in antibody engineering, the two companies will progress CDR-Life’s preclinical candidate, with the aim to preserve sight for patients with GA.

January 2020: Boehringer Ingelheim and Enleofen Bio Pte. Ltd. (Enleofen) announced the acquisition of worldwide exclusive rights to Enleofen’s preclinical interleukin-11 (IL-11) platform by Boehringer Ingelheim to develop first-in-class therapies across a broad range of fibro-inflammatory diseases.

About Boehringer Ingelheim
Boehringer Ingelheim, headquartered in Ingelheim am Rhein, Germany, is a global pharmaceutical company. The company is a research-driven pharma leader embracing many cultures and diverse societies. It has more than 51,000 employees across the world.

Prominent Global Investors

View all

Related News